Appointments

News & Events

Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board

May 30, 2017

Daix (France), 30 May 2017 – 07:30pm CEST – Inventiva (Euronext Paris – FR0013233012 – IVA), a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, announced today the appointment Dr Nanna Lüneborg to the board of Inventiva, succeeding Mr Philippe Goupit. With this appointment, Inventiva’s Board of Directors comprises eight directors (three women and five men), including four independent directors.

Nanna Lüneborg is a Principal of Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation.

Nanna Lüneborg has a background in medical research and life science venture capital. She completed her undergraduate studies at University of Oxford, PhD in Neuroscience from University College London, and MBA from the University of Cambridge. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ earlier this year. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.

On behalf of the Board of Directors and the Company as a whole, we warmly thank Philippe for his contribution to Inventiva’s development and wish him every success in his future projects;,” commented Frédéric Cren, Chairman and CEO of Inventiva. To succeed him, we are very pleased to welcome Nanna to our Board of Directors. Nanna’s experience will be valuable at this key stage in our development with the results of three clinical trials expected in 2018. We look forward to the advice and contribution she will bring.”;

“I am very pleased to be joining Inventiva’s Board of Directors. Inventiva has a promising portfolio of advanced products in fields that are stirring up significant interest in the pharmaceuticals industry. Being able to demonstrate positive results in NASH1, systemic sclerosis and MPS VI would constitute a major step forward for millions of patients who are still not receiving effective treatment,” added Dr Lüneborg. “This is an exciting time for the Company. Following the successful IPO, which gives it the financial means to realise its ambitions, I look forward to working in close collaboration with Inventiva’s Board of Directors and management team as the company moves ahead in the next key stages of its development.

About Novo Ventures:

Novo Ventures is part of Novo A/S, a private limited liability company, wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group and is responsible for managing the assets of the Foundation. Besides being the major shareholder in the Novo Group companies, including Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. It has offices in Copenhagen, San Francisco, Boston and London with a team of scientific and commercial experts actively supporting a portfolio of projects and companies. For further information visit www.novo.dk.

1 Non-Alcoholic Steatotic Hepatitis

 

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Julien Trosdorf / Yannick Tetzlaff

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.